BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30256411)

  • 1. Heme oxygenase-1 reduces the sensitivity to imatinib through nonselective activation of histone deacetylases in chronic myeloid leukemia.
    Wei D; Lu T; Ma D; Yu K; Li X; Chen B; Xiong J; Zhang T; Wang J
    J Cell Physiol; 2019 Apr; 234(4):5252-5263. PubMed ID: 30256411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heme oxygenase-1 contributes to imatinib resistance by promoting autophagy in chronic myeloid leukemia through disrupting the mTOR signaling pathway.
    Cao L; Wang J; Ma D; Wang P; Zhang Y; Fang Q
    Biomed Pharmacother; 2016 Mar; 78():30-38. PubMed ID: 26898422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.
    Ma D; Fang Q; Wang P; Gao R; Wu W; Lu T; Cao L; Hu X; Wang J
    J Biol Chem; 2015 May; 290(20):12558-71. PubMed ID: 25802333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
    Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
    Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.
    Mayerhofer M; Gleixner KV; Mayerhofer J; Hoermann G; Jaeger E; Aichberger KJ; Ott RG; Greish K; Nakamura H; Derdak S; Samorapoompichit P; Pickl WF; Sexl V; Esterbauer H; Schwarzinger I; Sillaber C; Maeda H; Valent P
    Blood; 2008 Feb; 111(4):2200-10. PubMed ID: 18024796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
    Sorrenti V; Pittalà V; Romeo G; Amata E; Dichiara M; Marrazzo A; Turnaturi R; Prezzavento O; Barbagallo I; Vanella L; Rescifina A; Floresta G; Tibullo D; Di Raimondo F; Intagliata S; Salerno L
    Eur J Med Chem; 2018 Oct; 158():937-950. PubMed ID: 30261468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.
    Tibullo D; Barbagallo I; Giallongo C; La Cava P; Parrinello N; Vanella L; Stagno F; Palumbo GA; Li Volti G; Di Raimondo F
    Curr Pharm Des; 2013; 19(15):2765-70. PubMed ID: 23092325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition.
    Wei D; Lu T; Ma D; Yu K; Zhang T; Xiong J; Wang W; Zhang Z; Fang Q; Wang J
    Life Sci; 2018 Oct; 211():224-237. PubMed ID: 30248347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation.
    Lu T; Wei D; Yu K; Ma D; Xiong J; Fang Q; Wang J
    Ann N Y Acad Sci; 2020 May; 1467(1):77-93. PubMed ID: 31930541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
    Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC
    Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells.
    Zhang J; Zhang M; Liang Y; Liu M; Huang Z
    Hematology; 2022 Dec; 27(1):43-52. PubMed ID: 34957936
    [No Abstract]   [Full Text] [Related]  

  • 13. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia.
    Mayerhofer M; Florian S; Krauth MT; Aichberger KJ; Bilban M; Marculescu R; Printz D; Fritsch G; Wagner O; Selzer E; Sperr WR; Valent P; Sillaber C
    Cancer Res; 2004 May; 64(9):3148-54. PubMed ID: 15126353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of
    Deng Y; Li X; Feng J; Zhang X
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
    Lee CR; Kang JA; Kim HE; Choi Y; Yang T; Park SG
    FEBS Lett; 2016 Feb; 590(3):358-68. PubMed ID: 26831735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
    Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
    Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.